Mild Hyperbaric Oxygen Therapy (mHBOT) at 1.3 ATA involves pressurizing the body to a level slightly above atmospheric pressure, equivalent to being approximately 10 feet below sea level. This pressure is considered mild and is typically achieved using soft-sided chambers that are portable and designed for wellness or chronic support rather than acute medical treatment. At 1.3 ATA, the therapy allows for increased oxygen dissolution in the blood plasma, cerebrospinal fluid, and other bodily fluids, independent of red blood cell hemoglobin, potentially enhancing cellular repair and reducing inflammation.

Despite the lower pressure and oxygen purity compared to clinical Hyperbaric Oxygen Therapy (HBOT), studies have shown that 1.3 ATA protocols can produce significant physiological benefits, including improvements in fatigue, cognitive function, and recovery from neurological conditions. For instance, research has demonstrated that patients receiving mHBOT at 1.3 ATA showed comparable improvements to those at higher pressures, with fewer side effects.